Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 7:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 299 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Interventions
dupilumab, Topical emollient (moisturizer)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Montgomery, Alabama • Fremont, California + 20 more
Conditions
Pigmentation
Interventions
Broadband Light
Device
Lead sponsor
Sciton
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Montclair, New Jersey
Conditions
Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ
Interventions
Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Combination Therapy for Atopic Dermatitis

NCT00119158
Conditions
Atopic Dermatitis
Interventions
Combination of pimecrolimus and fluticasone, pimecrolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Houston, Texas
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Skin Imaging With Technologies in Development

NCT00764920
Conditions
Pigmented Skin Lesion of Uncertain Nature
Interventions
non-invasive imaging modalities for assessment of skin
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
7 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Irvine, California
Conditions
Knee Injuries, Cartilage Injury, Cartilage Disease, Knee Discomfort
Interventions
Microfracture, Microfracture plus placement of Chondro-Gide® ACC
Procedure · Device
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Stamford, Connecticut • Johns Creek, Georgia
Conditions
Skin Lesion, Nevus
Interventions
DermTech PLA noninvasive adhesive biopsy
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
0 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Solid Tumor
Interventions
enzyme inhibitor therapy, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Skin Lesion, Skin Cancer, Skin Melanoma, Tumor Skin
Interventions
Oxygen
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Dysplastic Nevi
Interventions
Saucerization biopsy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Malignant Neoplasm, Metastatic Skin Squamous Cell Carcinoma, Metastatic Small Intestinal Adenocarcinoma, Rare Neoplastic Syndrome, Refractory Malignant Neoplasm, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Unresectable Malignant Neoplasm
Interventions
Atezolizumab, Cobimetinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers Results available

14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon

NCT02737618
Conditions
Dermal Irritation
Interventions
Trojan "Chameleon" Personal Lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Conditions
Lesion Skin, Seborrheic Keratosis, Skin Lesion, Benign Skin Tumor
Interventions
Nano-Pulse Stimulation (NPS)
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Scottsdale, Arizona • Edwards, Colorado • Coral Gables, Florida + 4 more
Completed Not applicable Interventional Accepts healthy volunteers

Skin Sensitization Test (Modified Draize-95 Test)

NCT03886987
Conditions
Skin Sensitisation
Interventions
Blue Non Sterile Powder Free Nitrile Examination Gloves
Device
Lead sponsor
Central Medicare Sdn. Bhd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fairfield, New Jersey
Conditions
Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions
Exemestane, Tamoxifen
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Conditions
Hypersensitivity
Interventions
Butenafine HCl 1% (BAY1896425), Positive Control-Sodium lauryl sulfate (SLS), Negative Control
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Conditions
Angiofibroma of Face, Tuberous Sclerosis
Interventions
Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment
Drug
Lead sponsor
Aucta Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

NCT00314262
Conditions
Precancerous Conditions
Interventions
Erlotinib & Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Psoriasis
Interventions
Daclizumab, NB-UVB
Drug · Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Conditions
Seborrheic Keratosis
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Miami, Florida • Newnan, Georgia + 6 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test

NCT01892657
Conditions
Skin Irritation
Interventions
Facial Moisturizer with SPF 50+
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Colorado Springs, Colorado
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions

NCT05742347
Conditions
Erythema, Maceration, Lesion Skin, Skin Folds
Interventions
DriGo Skin Protectant Textile
Device
Lead sponsor
Medline Industries
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lincoln, Nebraska